Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab with Chemotherapy +/- Ipilimumab N01 in Perioperative Treatment of Resectable Gastric/GEJ Adenocarcinoma
NCT07643623Phase 3Recruiting
- Sponsor
- Innovent Biologics
- Start
- Jul 2026
- Primary completion
- Dec 2031
- Countries
- 1
01
Overview
A Phase 3 trial of sintilimab, ipilimumab in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Innovent Biologics. Started Jul 2026; status: recruiting.
02
Drugs
sintilimabipilimumab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT07643623.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07643623.